vaborbactam   Click here for help

GtoPdb Ligand ID: 10871

Synonyms: compound 9f [PMID: 25782055] | RPX-7009 | RPX7009 | Vabomere (vaborbactam + meropenem)
Approved drug PDB Ligand
vaborbactam is an approved drug (FDA (2017), EMA (2018))
Compound class: Synthetic organic
Comment: Vaborbactam is a β-lactamase inhibitor [3]. Structurally it is based on a cyclic boronic acid pharmacophore.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 124.1
Molecular weight 297.08
XLogP 0.33
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(Cc1cccs1)N[C@H]1CC[C@H](OB1O)CC(=O)O
Isomeric SMILES O=C(Cc1cccs1)N[C@H]1CC[C@H](OB1O)CC(=O)O
InChI InChI=1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1
InChI Key IOOWNWLVCOUUEX-WPRPVWTQSA-N
No information available.
Summary of Clinical Use Click here for help
A combination of vaborbactam plus meropenem (Vabomere) is approved by the FDA as a treatment for serious urinary tract infections [2,4]. The same combination is authorised in the EU with the trade name Vaborem.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02168946 Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults Phase 3 Interventional Melinta Therapeutics, Inc. 1,6
NCT02166476 Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP Phase 3 Interventional Melinta Therapeutics, Inc. 5
External links Click here for help